Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study

Kallner, Helena Kopp; Christensson, Anna; Elmér, Caroline; Flam, Benjamin; Altman, Daniel

doi:10.1016/j.ejogrb.2016.05.048

Cited by 6 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 In addition, a recent prospective observational study evaluating the cardiovascular safety of mirabegron showed that the cardiovascular safety profile of mirabegron is satisfactory. 27 In the present study, elevated blood pressure was noted in both groups, occurring in 3.23% of the younger patients and 1.94% of the older patients. However, the incidence of hypertension was not superior to those reported in a previous study (i.e.…”

Section: Discussionsupporting

confidence: 56%

“…A systemic review concluded that mirabegron has an occurrence of adverse cardiovascular effects comparable with those of antimuscarinic agents . In addition, a recent prospective observational study evaluating the cardiovascular safety of mirabegron showed that the cardiovascular safety profile of mirabegron is satisfactory . In the present study, elevated blood pressure was noted in both groups, occurring in 3.23% of the younger patients and 1.94% of the older patients.…”

Section: Discussionsupporting

confidence: 55%

See 1 more Smart Citation

Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities

Lee

Kuo

2018

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 56%

Section: Discussionsupporting

confidence: 55%

Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities

Lee

Kuo

2018

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

“…Mirabegron is the first beta‐3 adrenoceptor agonist approved for the treatment of patients with OAB . Its safety and efficacy have been proven in various clinical trials to be comparable to those of currently prescribed antimuscarinics . In addition, this novel medication is expected to have a favorable adverse effect profile owing to its pharmacological mechanism of action, leading to higher long‐term persistence rates .…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and persistence of mirabegron as a first‐line treatment in patients with overactive bladder in real‐life practice

Shin

Choo

2019

LUTS

View full text Add to dashboard Cite

Objectives: To evaluate the effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder (OAB) in real-life practice. Methods:We retrospectively analyzed patients with OAB who received mirabegron (50 mg) as a first-line treatment. According to treatment course, patients were divided into three groups, (a) mirabegron only (monotherapy group), (b) mirabegron and anticholinergics (add-on group), and (c) mirabegron replaced with another treatment (switch group). The patients' symptoms were documented with a voiding diary including an urgency scale and a patient perception of treatment benefit questionnaire (PPTB). Follow-up was at 4 weeks after initial treatment and then 2 months later, according to our routine protocol.Results: A total of 196 patients were included: 128 patients (65.3%) received monotherapy and 60 patients (30.6%) received add-on therapy. Eight patients discontinued mirabegron and switched to another treatment modality. The add-on group had more episodes of baseline urinary frequency, nocturia and urgency than the monotherapy group (P = 0.011, 0.001, and 0.006, respectively). In the monotherapy group, mean daily frequency, nocturia, urgency episodes, and urgency urinary incontinence were improved (P < 0.05) after mirabegron treatment.The persistence of mirabegron monotherapy was 68.0% at 3 months, 54.4% at 6 months, and 39.4% at 12 months. Treatment-naïve patients had better persistency than previously anticholinergics-treated patients. Conclusions:Mirabegron is an effective first-line therapy for OAB, but has a persistence rate of 39.4% at 12 months. Patients with severe baseline OAB symptoms tended to require add-on therapy during follow-up.

show abstract

Advances in Pharmacotherapy for the Treatment of Overactive Bladder

Suskind

2019

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study

Cited by 6 publications

References 26 publications

Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities

Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities

Effectiveness and persistence of mirabegron as a first‐line treatment in patients with overactive bladder in real‐life practice

Advances in Pharmacotherapy for the Treatment of Overactive Bladder

Contact Info

Product

Resources

About